High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Portfolio Pulse from
New high-cost gene therapies for sickle cell disease are prompting insurers and Medicaid programs to explore new payment models. CVS Health is considering new risk pool arrangements to manage these costs.
February 18, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CVS Health is exploring new risk pool arrangements to manage the high costs of new gene therapies for sickle cell disease.
CVS Health is directly involved in managing the costs of new gene therapies, which could impact their financial strategies and healthcare offerings. However, the immediate stock price impact is neutral as this is a strategic consideration rather than an immediate financial change.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80